Product Introduction: AJAPRIDE-PM 1

AJAPRIDE-PM 1 is a widely prescribed triple-combination antidiabetic medication manufactured by Ajantha. Composed of 1mg of Glimepiride (a sulfonylurea), 500mg of Metformin Hydrochloride Sustained-Release (SR), and 15mg of Pioglitazone Hydrochloride (a thiazolidinedione), it is indicated for glycemic control in adult patients diagnosed with Type 2 Diabetes Mellitus when double combination therapy is insufficient.

Primary Indications

• Management of Type 2 Diabetes Mellitus in adults for optimal glycemic control.
• Improving insulin secretion, reducing insulin resistance, and restricting hepatic glucose production.
• Reducing the long-term risk of diabetic microvascular and macrovascular complications.

Clinical Benefits

• Triple Pathway Control: Glimepiride stimulates insulin release, Metformin reduces hepatic glucose, and Pioglitazone enhances insulin sensitivity.
• HbA1c Optimization: Assists in achieving and maintaining target HbA1c (glycosylated hemoglobin) levels.
• Sustained-Release Metformin: Smooth, gradual drug release minimizes gastrointestinal side effects.

Possible Side Effects

Common side effects may include:

• Gastrointestinal issues (nausea, metallic taste, abdominal bloating, transient diarrhea).
• Weight gain or peripheral edema (fluid retention) due to Pioglitazone.
• Hypoglycemia (low blood sugar), especially when co-administered with sulfonylureas or insulin.

How to Take AJAPRIDE-PM 1

• Take the tablet daily, with or immediately after your morning meal to minimize stomach upset and prevent hypoglycemia.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or split.
• Do not stop taking the drug abruptly without consulting your endocrinologist.

Mechanism of Action

AJAPRIDE-PM 1 works through three distinct mechanisms:

• Glimepiride: Binds to ATP-sensitive potassium channels on pancreatic beta-cells, causing depolarization and opening of calcium channels, triggering the release of insulin.
• Metformin: Decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.
• Pioglitazone: Activates peroxisome proliferator-activated receptor-gamma (PPAR-gamma), regulating genes involved in glucose control and lipogenesis, increasing peripheral insulin sensitivity.

Safety Warnings

• Lactic Acidosis: Metformin carries a rare but serious risk of lactic acidosis. Avoid in severe renal impairment.
• Fluid Retention: Pioglitazone can cause fluid retention, which may lead to or exacerbate congestive heart failure. Contraindicated in NYHA Class III/IV heart failure.
• Pregnancy & Nursing: Strictly contraindicated. Avoid use.

Patient Advice

• Always carry a rapid-acting source of sugar (like glucose powder or fruit juice) in case of hypoglycemia.
• Monitor your weight and check for signs of swelling in your lower limbs. Report sudden weight gain immediately.
• Ensure regular monitoring of liver enzymes, kidney function, and HbA1c levels.

Fact Box

Drug Interactions

• Corticosteroids: May increase blood glucose levels, reducing drug efficacy.
• Gemfibrozil: May increase Pioglitazone exposure and side effect risks.
• Iodinated Contrast Media: Increased risk of lactic acidosis; hold Metformin temporarily.

User Feedback

• Patients report excellent control of their fasting and post-meal sugar levels, with a significant drop in HbA1c.
• Initial stomach bloating is common but typically fades away after 7 to 10 days of consistent use.